We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

27 hedge funds and large institutions have $12.6M invested in Regulus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

37.41% more ownership

Funds ownership: 4.16% → 41.57% (+37%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

25% less funds holding

Funds holding: 36 → 27 (-9)

31% less capital invested

Capital invested by funds: $18.1M → $12.6M (-$5.52M)

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

Holders
27
Holders Change
-9
Holders Change %
-25%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
10
Closed
16
Calls
$1.28M
Puts
–
Net Calls
+$1.28M
Net Calls Change
+$1.09M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$58.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$57.4K
3
BlackRock
BlackRock
New York
+$51.4K
4
Renaissance Technologies
Renaissance Technologies
New York
+$35.8K
5
VF
Virtu Financial
New York
+$24.8K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$57.2K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$55K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$51K
4
Two Sigma Investments
Two Sigma Investments
New York
-$34K
5
GC
Grimes & Company
Massachusetts
-$26K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$6.01M -$2 -1 -0%
NMC
2
NEA Management Company
Maryland
$2.99M – – –
DCM
3
DAFNA Capital Management
California
$1.15M -$2 -1 -0%
Vanguard Group
4
Vanguard Group
Pennsylvania
$772K +$11.9K +4,899 +1%
Victory Capital Management
5
Victory Capital Management
Texas
$459K -$4.36K -1,797 -0.8%
SCM
6
Sarissa Capital Management
Connecticut
$383K -$5 -2 -0%
IC
7
Ikarian Capital
Texas
$217K -$57.2K -23,572 -18%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$148K +$16.9K +6,950 +11%
State Street
9
State Street
Massachusetts
$86K +$58.4K +24,070 +136%
Renaissance Technologies
10
Renaissance Technologies
New York
$58K +$35.8K +14,760 +111%
Citadel Advisors
11
Citadel Advisors
Florida
$49K +$57.4K +23,655 New
Commonwealth Equity Services
12
Commonwealth Equity Services
Massachusetts
$45K +$21.6K +8,900 +68%
BlackRock
13
BlackRock
New York
$45K +$51.4K +21,183 +3,057%
Northern Trust
14
Northern Trust
Illinois
$37K +$2.83K +1,164 +7%
BFM
15
Boothbay Fund Management
New York
$24K -$2K -823 -7%
VF
16
Virtu Financial
New York
$21K +$24.8K +10,205 New
UBS Group
17
UBS Group
Switzerland
$17K +$5.05K +2,081 +34%
Acadian Asset Management
18
Acadian Asset Management
Massachusetts
$17K +$19.5K +8,049 New
Group One Trading
19
Group One Trading
Illinois
$15K -$1.92K -791 -10%
TRCT
20
Tower Research Capital (TRC)
New York
$5K -$1.35K -556 -20%
Bank of America
21
Bank of America
North Carolina
$2K +$2.43K +1,001 New
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$1K -$19 -8 -1%
Wells Fargo
23
Wells Fargo
California
$1K -$10 -4 -0.6%
CB
24
Community Bank
New York
$1K – – –
Simplex Trading
25
Simplex Trading
Illinois
$1K +$1.28K +527 New
1
2

RGLS Hedge Fund Activity: Q2 2022 in Review

27 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2022, worth a combined $12.6M — down 31% from $18.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of RGLS and 7 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was State Street, adding an estimated $58.4K. The largest seller was Ikarian Capital, cutting an estimated $57.2K.

  • 27 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2022, down from 36 in Q1 2022.
  • Funds reported $12.6M of Regulus Therapeutics stock for Q2 2022, down 31% quarter-over-quarter.
  • 7 funds opened new Regulus Therapeutics positions in Q2 2022 and 16 closed out, a net change of -9 holders.
  • The largest Regulus Therapeutics buyer in Q2 2022 was State Street, an estimated $58.4K added.
  • The largest Regulus Therapeutics seller in Q2 2022 was Ikarian Capital, an estimated $57.2K sold.

Based on aggregated 13F filings for Q2 2022.